Latest Publications

@article{samadder_synthesis_2017,

title = {Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.},

author = {Pounami Samadder and Tereza Suchánková and Ondřej Hylse and Prashant Khirsariya and Fedor Nikulenkov and Stanislav Drápela and Nicol Straková and Petr Vaňhara and Kateřina Vašíčková and Hana Kolářová and Lucia Binó and Miroslava Bittová and Petra Ovesná and Peter Kollár and Radek Fedr and Milan Ešner and Josef Jaroš and Aleš Hampl and Lumír Krejčí and Kamil Paruch and Karel Souček},

doi = {10.1158/1535-7163.MCT-17-0018},

issn = {1538-8514 1535-7163},

year  = {2017},

date = {2017-09-01},

journal = {Molecular cancer therapeutics},

volume = {16},

number = {9},

pages = {1831–1842},

abstract = {Checkpoint-mediated dependency of tumor cells can be deployed to selectively kill them without substantial toxicity to normal cells. Specifically, loss of CHK1, a serine threonine kinase involved in the surveillance of the G(2)-M checkpoint in the presence of replication stress inflicted by DNA-damaging drugs, has been reported to dramatically influence the viability of tumor cells. CHK1's pivotal role in maintaining genomic stability offers attractive opportunity for increasing the selectivity, effectivity, and reduced toxicity of chemotherapy. Some recently identified CHK1 inhibitors entered clinical trials in combination with DNA antimetabolites. Herein, we report synthesis and profiling of MU380, a nontrivial analogue of clinically profiled compound SCH900776 possessing the highly unusual N-trifluoromethylpyrazole motif, which was envisioned not to undergo metabolic oxidative dealkylation and thereby provide greater robustness to the compound. MU380 is a selective and potent inhibitor of CHK1 which sensitizes a variety of tumor cell lines to hydroxyurea or gemcitabine up to 10 times. MU380 shows extended inhibitory effects in cells, and unlike SCH900776, does not undergo in vivo N-dealkylation to the significantly less selective metabolite. Compared with SCH900776, MU380 in combination with GEM causes higher accumulation of DNA damage in tumor cells and subsequent enhanced cell death, and is more efficacious in the A2780 xenograft mouse model. Overall, MU380 represents a novel state-of-the-art CHK1 inhibitor with high potency, selectivity, and improved metabolic robustness to oxidative N-dealkylation. Mol Cancer Ther; 16(9); 1831-42. ©2017 AACR.},

note = {Place: United States},

keywords = {Animal, Animals, Antineoplastic Agents/*chemical synthesis/*pharmacology, Apoptosis/drug effects, Biomarkers, Cell Cycle Checkpoints/drug effects, Cell Cycle/drug effects, Cell Line, Checkpoint Kinase 1/*antagonists & inhibitors, Dealkylation/drug effects, Disease Models, Dose-Response Relationship, Drug, Drug resistance, Humans, Methylation, Mice, Molecular Structure, Neoplasm/*drug effects, Protein Kinase Inhibitors/*chemical synthesis/*pharmacology, Pyrazoles/pharmacology, Pyrimidines/pharmacology, Tumor, Xenograft Model Antitumor Assays},

pubstate = {published},

tppubtype = {article}

}

@article{pernicova_role_2014,

title = {The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.},

author = {Zuzana Pernicová and Eva Slabáková and Radek Fedr and Šárka Šimečková and Josef Jaroš and Tereza Suchánková and Jan Bouchal and Gvantsa Kharaishvili and Milan Král and Alois Kozubík and Karel Souček},

doi = {10.1186/1476-4598-13-113},

issn = {1476-4598},

year  = {2014},

date = {2014-05-01},

journal = {Molecular cancer},

volume = {13},

pages = {113},

abstract = {BACKGROUND: Tumor heterogeneity and the plasticity of cancer cells present challenges for effective clinical diagnosis and therapy. Such challenges are epitomized by neuroendocrine transdifferentiation (NED) and the emergence of neuroendocrine-like cancer cells in prostate tumors. This phenomenon frequently arises from androgen-depleted prostate adenocarcinoma and is associated with the development of castration-resistant prostate cancer and poor prognosis. RESULTS: In this study, we showed that NED was evoked in both androgen receptor (AR)-positive and AR-negative prostate epithelial cell lines by growing the cells to a high density. Androgen depletion and high-density cultivation were both associated with cell cycle arrest and deregulated expression of several cell cycle regulators, such as p27Kip1, members of the cyclin D protein family, and Cdk2. Dual inhibition of Cdk1 and Cdk2 using pharmacological inhibitor or RNAi led to modulation of the cell cycle and promotion of NED. We further demonstrated that the cyclic adenosine 3', 5'-monophosphate (cAMP)-mediated pathway is activated in the high-density conditions. Importantly, inhibition of cAMP signaling using a specific inhibitor of adenylate cyclase, MDL-12330A, abolished the promotion of NED by high cell density. CONCLUSIONS: Taken together, our results imply a new relationship between cell cycle attenuation and promotion of NED and suggest high cell density as a trigger for cAMP signaling that can mediate reversible NED in prostate cancer cells.},

note = {Place: England},

keywords = {*Cell Transdifferentiation/drug effects, Androgen/metabolism, Androgens/pharmacology, CDC2 Protein Kinase, Cell Count, Cell Cycle Checkpoints/drug effects, Cell Line, Cyclic AMP/metabolism, Cyclin-Dependent Kinase 2/metabolism, Cyclin-Dependent Kinases/metabolism, Epithelial Cells/drug effects/enzymology/pathology, Humans, Immunohistochemistry, Male, Neuroendocrine Cells/drug effects/*pathology, Prostatic Neoplasms/*pathology, Protein Kinase Inhibitors/pharmacology, Receptors, Signal Transduction/drug effects, Tumor},

pubstate = {published},

tppubtype = {article}

}

@article{steinmetz_oncogene_2014,

title = {The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.},

author = {Birgit Steinmetz and Hubert Hackl and Eva Slabáková and Ilse Schwarzinger and Monika Smějová and Andreas Spittler and Itziar Arbesu and Medhat Shehata and Karel Souček and Rotraud Wieser},

doi = {10.4161/15384101.2014.946869},

issn = {1551-4005 1538-4101},

year  = {2014},

date = {2014-01-01},

journal = {Cell cycle (Georgetown, Tex.)},

volume = {13},

number = {18},

pages = {2931–2943},

abstract = {The product of the ecotropic virus integration site 1 (EVI1) gene, whose overexpression is associated with a poor prognosis in myeloid leukemias and some epithelial tumors, regulates gene transcription both through direct DNA binding and through modulation of the activity of other sequence specific transcription factors. Previous results from our laboratory have shown that EVI1 influenced transcription regulation in response to the myeloid differentiation inducing agent, all-trans retinoic acid (ATRA), in a dual manner: it enhanced ATRA induced transcription of the RARβ gene, but repressed the ATRA induction of the EVI1 gene itself. In the present study, we asked whether EVI1 would modulate the ATRA regulation of a larger number of genes, as well as biological responses to this agent, in human myeloid cells. U937 and HL-60 cells ectopically expressing EVI1 through retroviral transduction were subjected to microarray based gene expression analysis, and to assays measuring cellular proliferation, differentiation, and apoptosis. These experiments showed that EVI1 modulated the ATRA response of several dozens of genes, and in fact reinforced it in the vast majority of cases. A particularly strong synergy between EVI1 and ATRA was observed for GDF15, which codes for a member of the TGF-β superfamily of cytokines. In line with the gene expression results, EVI1 enhanced cell cycle arrest, differentiation, and apoptosis in response to ATRA, and knockdown of GDF15 counteracted some of these effects. The potential clinical implications of these findings are discussed.},

note = {Place: United States},

keywords = {*Oncogenes, acute myeloid leukemia, acute promyelocytic leukemia, all-trans retinoic acid, AML, APL, Apoptosis, Apoptosis/drug effects, Ar, ATRA, ATRA regulation, Cell Cycle, Cell Cycle Checkpoints/drug effects, Cell Differentiation/drug effects, dimethyl sulfoxide, DMSO, DNA-Binding Proteins/genetics/*metabolism, Down-Regulation/drug effects, Em, Epithelial Cells/drug effects/metabolism, Er, EVI1, EVI1 modulation, EVI1 regulation, false discovery rate, FBS, FC, FDR, fetal bovine serum, fold change, GDF15, Gene Expression Profiling, Gene Knockdown Techniques, Genetic/*drug effects, GFP, green fluorescent protein, Growth Differentiation Factor 15/genetics/metabolism, HL-60 Cells, Humans, mcoEvi1, MDS, MDS1 and EVI1 Complex Locus Protein, murine codon optimized Evi1, myelodysplastic syndrome, Myeloid Cells/drug effects/*metabolism, myeloid differentiation, penicillin streptomycin glutamine, Proto-Oncogenes/genetics, PSG, RAR, RARE, Real-Time Polymerase Chain Reaction, Reproducibility of Results, retinoic acid receptor, retinoic acid response element, SE, standard error, Transcription, Transcription Factors/genetics/*metabolism, Tretinoin/*pharmacology},

pubstate = {published},

tppubtype = {article}

}